CP-532,903 is a selective adenosine A3 subtype receptor agonist. It has antiinflammatory effects and has been shown to reduce superoxide generation in damaged tissues,[1] and protects against tissue damage following myocardial ischemia,[2] mediated via an interaction with ATP-sensitive potassium channels.[3]

References

  1. ^ Van Der Hoeven, D.; Wan, T. C.; Auchampach, J. A. (2008). "Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils". Molecular Pharmacology. 74 (3): 685–696. doi:10.1124/mol.108.048066. PMC 2574951. PMID 18583455.
  2. ^ Tracey, W. R.; Magee, W. P.; Oleynek, J. J.; Hill, R. J.; Smith, A. H.; Flynn, D. M.; Knight, D. R. (2003). "Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury". American Journal of Physiology. Heart and Circulatory Physiology. 285 (6): H2780-7. doi:10.1152/ajpheart.00411.2003. PMID 12919933.
  3. ^ Wan, Tina C.; Ge, Zhi-Dong; Tampo, Akihito; Mio, Yasushi; Bienengraeber, Martin W.; Tracey, W. Ross; Gross, Garrett J.; Kwok, Wai-Meng; Auchampach, John A. (2008). "The A3 Adenosine Receptor Agonist CP-532,903 [ N 6-(2,5-Dichlorobenzyl)-3′-aminoadenosine-5′- N -methylcarboxamide] Protects against Myocardial Ischemia/Reperfusion Injury via the Sarcolemmal ATP-Sensitive Potassium Channel". Journal of Pharmacology and Experimental Therapeutics. 324: 234–243. doi:10.1124/jpet.107.127480. PMC 2435594. PMID 17906066.
Allikas: https://en.wikipedia.org/wiki/CP-532,903
No tags for this post.